SciSparc is a specialty pharmaceutical company developing cannabinoid-based treatments for neurological disorders.
CLINICAL TRIALS: Yes.
8 total granted patents with 5 in the US and others in Japan and Australia. CannAmide, which is the company’s proprietary Palmitoylethanolamide formulation is trademarked in the US. The company is focused on Tourette syndrome, Status Epilepticus, Alzheimer’s disease, Autism spectrum disorder and pain and inflammation.
PRODUCTS:
SCI-110 is the company’s proprietary drug candidate containing Dronabinol with the endocannabinoid PEA and is designed to stimulate cannabinoid receptors across the CNS and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC, the expected benefits of SCI-110 are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, side effects and adverse events with indications being investigated are TS, OSA and Alzheimer’s Disease and Agitation. The SCI-110 phase 2A clinical trial for Tourette syndrome is led by Yale University.
SCI-210 is the company’s proprietary drug candidate containing CBD and PEA developed under the regulation of the Israeli Medical Cannabis Agency. The company plans to further develop the product for markets outside Israel. Indications investigated are autism and status epilepticus.
SCI-160 is the company’s proprietary synthetic CB2 receptor agonist created for the treatment of pain and is currently in pre-clinical studies. The CB2 receptor agonist HU-433 used in this formulation is protected under a patent granted in the US as well as Europe and was invented and synthesized by Professor Raphael Mechoulam, chairman of the SciSparc Scientific Advisory Board.
CannAmide is an immediate unique PEA oral formulation for the reduction of chronic pain and inflammation coming in a tablet containing 400mg active pharmaceutical ingredient.
NEWS & PARTNERSHIPS:
2024
The company signed a merger agreement to merge with AutoMax Motors, a vehicle importer in Israel, with the company’s shareholders holding approximately 50.01% of the share capital of the new company.
The company signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program for pain treatment. Polyrizon will receive an exclusive, royalty-bearing global license to develop and sublicense SCI-160. SciSpark will receive Polyrizon securities for the value of 3 million USD as well as potential milestone fees of approximately 3 million USD in cash if certain development milestones will be met, and royalties. SCI-160 is a synthetic combination of cannabinoids and N-acylethanolamines.
2025
The company announced that the board of directors gave the go ahead to launch an innovative initiative to advance 3D protein modeling using quantum computing technology, hoping to transform drug discovery by potentially achieving unprecedented accuracy in predicting protein structures and interactions with their ligands, potentially paving the way for breakthroughs in structural biology and personalized medicine.
The company enetered into an agreement with AutoMax Motors to merge but was mututally terminated after AutoMax faced uncertainty in its ability to meet the merger’s closing conditions.
The company bought a controlling stake (between 75-84% in Miza III Ventures. After closure, Miza rebranded to NeuroThera Labs with operations in pharmaceutical and nutritional supplement markets. The company or a 3rd party will provide up to 1 million CAD in capital through a 2-year, 7% convertible note which allows a conversion into as many as 4 million Miza shares at 0.25 CAD per share. Miza will in turn issue 4 million warrants exercisable at the same price for a period of 5 years.
The company announced intent to acquire key endoscopy intellectual property from Xylo Technologies, signalling future exansion beyond its core neuroscience pipeline into medical device commercialization. The acquisition gives SciSparc direct ownership of the technology as well as commercialization rights and the company will issue equity equal to 19.99% of its outstanding shares upon closing.